Clinical pharmacology

Capital Rx Announces Collaboration with Walmart to Expand Prescription Drug Cost Savings

Tuesday, July 7, 2020 - 1:00pm

Capital Rx and Walmart are the first to offer employers a unit price for all prescriptions across retail, mail and specialty.

Key Points: 
  • Capital Rx and Walmart are the first to offer employers a unit price for all prescriptions across retail, mail and specialty.
  • Working with Capital Rx will allow us to do the same for prescription drugs, said Luke Kleyn, Vice President, Walmart Health and Wellness.
  • Capital Rx is making great strides in redefining the way prescription drugs are priced and administered in the United States.
  • Through our collaboration with Walmart, Capital Rx brings the purchasing experience of an efficient market to specialty and mail drugs, said Loiacono.

Aesthetics Biomedical® Names World Renowned Experts to Prestigious Clinical Advisory Board

Monday, July 6, 2020 - 4:00pm

Grant Stevens, Steven Dayan, Michael DeWolfe, and Stephen Ronan have been appointed to the company's Clinical Advisory Board (CAB).

Key Points: 
  • Grant Stevens, Steven Dayan, Michael DeWolfe, and Stephen Ronan have been appointed to the company's Clinical Advisory Board (CAB).
  • With this group of renowned physicians serving as our Clinical Advisory Board, they will help us achieve our goals and maintain the highest company standards while forging new paths and standards within the industry.
  • We have meticulously selected this impressive team to continue to establish ABM's leadership within the field of aesthetics" says MaryAnn Guerra, CEO of Aesthetics Biomedical.
  • CAB members will also represent Aesthetics Biomedical at industry events, conferences, drafting of scientific papers and participate in clinical trials.

Inventiva announces the decision by the investigator to reduce the number of patients in the ongoing Phase II trial evaluating lanifibranor in type 2 diabetes patients (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)

Monday, July 6, 2020 - 7:00am

Pierre Broqua, CSO and cofounder of Inventiva, stated: We are very pleased with this decision following the positive results of lanifibranor during the Phase IIb clinical trial in NASH.

Key Points: 
  • Pierre Broqua, CSO and cofounder of Inventiva, stated: We are very pleased with this decision following the positive results of lanifibranor during the Phase IIb clinical trial in NASH.
  • Type 2 diabetes patients with NASH are generally exposed to an increased risk of poor clinical outcomes and are therefore in a critical need for an efficacious NASH treatment.
  • Inventiva recently announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH.
  • Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (Euronext: IVA ISIN: FR0013233012).

GenSight Biologics Reports Sustained Efficacy and Safety Among LHON Patients Three Years After LUMEVOQ® Treatment

Monday, July 6, 2020 - 6:30am

To date, across clinical trials and cases of compassionate use, 194 patients have been treated with LUMEVOQ, with many followed for at least 3 years post-injection.

Key Points: 
  • To date, across clinical trials and cases of compassionate use, 194 patients have been treated with LUMEVOQ, with many followed for at least 3 years post-injection.
  • The dose used in LUMEVOQ treatment, which introduces 9x1010 vg per eye, has been shown to result in negligible biodissemination.
  • The primary objective is to assess the long-term safety of intravitreal LUMEVOQ administration up to 5 years post-treatment.
  • The secondary objective is to assess the long-term treatment efficacy of the therapy and the quality of life (QoL) in subjects up to 5 years post-treatment.

Kitov Pharma Issues CEO Shareholder Letter Providing Business Update

Thursday, July 2, 2020 - 1:34pm

Importantly, following the recent launch of CONSENSI in the U.S., this drug is expected to begin generating royalty revenue for Kitov this year.

Key Points: 
  • Importantly, following the recent launch of CONSENSI in the U.S., this drug is expected to begin generating royalty revenue for Kitov this year.
  • Our core objective is to become a recognized leader in the oncology field and to make a significant impact on patients lives.
  • We look forward to providing you with further updates on these ongoing activities as events warrant.
  • These Phase 1 results are encouraging and indicate that CM24 at higher doses warrants further evaluation in a larger clinical study.

Cardinal Health to Webcast Discussion of Fourth-Quarter and Year-End Results for Fiscal Year 2020 on August 6

Thursday, July 2, 2020 - 11:55am

The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern.

Key Points: 
  • The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern.
  • To access the webcast and corresponding slide presentation, go to the Investor Relations page at ir.cardinalhealth.com .
  • To combat prescription drug misuse, the Cardinal Health Foundation and its education partners created Generation Rx, a national drug preventioneducation and awareness program.
  • Cardinal Health is backed by nearly 100 years of experience with operations in nearly 46 countries.

COVID-19 Projections Show New Emerging Risk for Virus Resurgence in Mid-Atlantic, Midwest Counties

Wednesday, July 1, 2020 - 7:12pm

The model, which provides four-week COVID-19 case projections across more than 500 counties, is once again showing increasing risk for virus resurgence in many communities that have been quiet for some time.

Key Points: 
  • The model, which provides four-week COVID-19 case projections across more than 500 counties, is once again showing increasing risk for virus resurgence in many communities that have been quiet for some time.
  • This includes cities along the I-95 corridor, such as Baltimore and Wilmington, Del., many metropolitan areas in Ohio and several rural counties in Colorado.
  • The researchers suggest that increased travel as communities reopen, combined with lack of vigilance and adherence to masking recommendations, is creating this renewed risk to former areas of concern.
  • A scientific review of the team's model and findings is available as a pre-print article ahead of peer review on medRxiv .

Illinois-Wisconsin Health System Partners with Medicom Health to Lower Patient Prescription Costs

Tuesday, June 30, 2020 - 9:31pm

Mercyhealth is a regional health system with seven hospitals and 85 primary and specialty care locations throughout 50 northern Illinois and southern Wisconsin communities.

Key Points: 
  • Mercyhealth is a regional health system with seven hospitals and 85 primary and specialty care locations throughout 50 northern Illinois and southern Wisconsin communities.
  • Medicom Health's new Rx Savings Assistant software is a simple way for hospital systems to instantly increase prescription fills by making them more affordable for more patients.
  • As soon as this solution is turned on, every qualified patient is eligible for effortless access to discounts for any prescription.
  • "Dramatically reducing the cost of medications for patients improves their adherence and ultimately their health," says Will Sigsbee, CEO of Medicom Health.

Matinas BioPharma Resumes Enrollment in the ENHANCE-IT and EnACT Clinical Trials

Tuesday, June 30, 2020 - 9:15pm

We believe we have taken the appropriate steps to ensure the safety of clinical trial participants and caregivers and we remain grateful for their commitment to our important clinical work.

Key Points: 
  • We believe we have taken the appropriate steps to ensure the safety of clinical trial participants and caregivers and we remain grateful for their commitment to our important clinical work.
  • The Company expects to complete enrollment in August of 2020, with topline data available in the first quarter of 2021.
  • Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions.
  • Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.

DrFirst's Next-Generation SmartSig 2.0 Solution Improves the Quality of Medication History to Help Protect Patients from Adverse Drug Events

Tuesday, June 30, 2020 - 12:55pm

In an initial study with six health systems, SmartSig 2.0 further enhanced the quality of structured and codified sigs over the previous version.

Key Points: 
  • In an initial study with six health systems, SmartSig 2.0 further enhanced the quality of structured and codified sigs over the previous version.
  • On discharge, an estimated 66% of data is missing essential prescription instructions, or sigs, increasing the risk of adverse drug events that compromise patient safety.
  • DrFirst's SmartSig is incorporated into the company's MedHx solution, which provides more complete, clean, and consumable patient medication history for the medication reconciliation process.
  • "More importantly, SmartSig has the potential to reduce adverse drug events, which are blamed for more than 100,000 deaths per year."